<DOC>
	<DOCNO>NCT00845351</DOCNO>
	<brief_summary>The objective pilot study establish safety tolerability short-term therapy bexarotene patient 's Cushing 's disease , study clinical , biochemical , cellular effect preoperative five-day course bexarotene patient undergo transsphenoidal surgery .</brief_summary>
	<brief_title>Preoperative Bexarotene Treatment Cushing 's Disease</brief_title>
	<detailed_description>Cushing 's disease refers condition glucocorticoid excess cause adrenocorticotropic hormone ( ACTH ) produce pituitary tumor , account 10-15 % pituitary tumor . The majority corticotroph tumor microadenomas time diagnosis , accurate surgical histologic identification tumor challenge . ACTH produce corticotroph cell within anterior pituitary via precursor pro-opiomelanocortin ( POMC ) . In physiologic pathologic condition promoter POMC regulate multiple transcription factor include AP-1 Nurr77 . Retinoic acid show inhibit activation POMC promoter corticotroph tumor cell culture via disruption Nurr77 transcriptional activity . The expression orphan nuclear receptor term chicken ovalbumin upstream promoter-transcription factor I ( COUP-TFI ) antagonize retinoic acid signaling , report present normal corticotroph cell , lack adenomatous corticotroph cell tissue culture study . Through retrospective analysis 34 human corticotroph tumor demonstrate consistent lack COUP-TFI 100 % microadenomas visible , measure less 5 millimeter preoperative MRI . In total , 85 % tumor study showed absence COUP-TFI . Based vitro data rat human corticotroph tumor , cell lack COUP-TFI vulnerable retinoid-induced cell death via Nurr77-mediated apoptosis , effect reverse COUP-TFI gene transfection . In 2006 , Castillo et al . publish result six-month trial randomize 44 dog Cushing 's disease RXR agonist ( 9-cis retinoic acid ) , ketoconazole . RXR agonist therapy outperform ketoconazole endpoint , result normalization ACTH cortisol level 100 % subject complete study , improve morbidity mortality . All dog treat RXR agonist remain remission duration 6 12 month post-treatment followup . This pilot study involve inpatient admission General Clinical Research Center 5 day prior schedule transsphenoidal surgery . During five day study individual receive RXR-agonist bexarotene FDA approve dose 300 mg/m2/day . Clinical sign symptom acute adrenal insufficiency monitor routinely throughout 24-hour period . Baseline twice-daily biochemical analysis ACTH cortisol perform . 24-hour urine collection cortisol obtain pre-treatment last 24-hours treatment . Laboratory safety analysis include serial comprehensive metabolic panel monitor liver kidney function , complete blood count monitor neutropenia , well thyroid function study monitor central hypothyroidism develop therapy .</detailed_description>
	<mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
	<mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<criteria>Age 1865 Clinical biochemical diagnosis Cushing 's disease establish clinical history , physical exam , definitive biochemical testing : 1 . Persistent hypercortisolemia establish 24 hour urine free cortisol measurement 2 . Confirmation pituitarydependent hypercortisolemia 1 . ACTH level normal elevate , clinically necessary , one following : 1 . Suppression 24 hour urine free cortisol either 48hour dexamethasone suppression test , suppression serum cortisol overnight highdose ( 8 mg ) dexamethasone suppression test OR 2 . Inferior Petrosal Sinus Sampling ( IPSS ) study Pituitary MRI perform within three month enrollment Health status deem appropriate transsphenoidal surgery neurosurgical preoperative evaluation University Virginia Pituitary Clinic Age less 18 great 65 Pregnant nursing mother Previous surgical , medical , radiation therapy involve pituitary fossa History malignancy , solid hematogenous History intracranial disease , injury intracranial surgical procedure Renal impairment GFR estimate &lt; 60 mL/min/1.73 m2 History liver disease , baseline liver transaminase level &gt; 50 % upper limit normal Fasting Triglycerides &gt; 200 mg/dL History pancreatitis Pituitary macroadenoma ( &gt; 1 cm ) measure MRI perform within 3 month enrollment Previous treatment Cushing 's disease include surgery , radiation , medical therapy : 1 . Ketoconazole 2 . Metyrapone 3 . Aminoglutethimide 4 . Mitotane Oral systemic glucocorticoid use last six month Intraarticular injection glucocorticoid last year Current use Ketoconazole , itraconazole , erythromycin , gemfibrozil , grapefruit juice , inhibitor cytochrome P450 3A4 Any disability cognitive , educational , language barrier would inhibit subject 's ability adequately understand verbal write material consent process despite use standard language translation service available clinic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Cushing 's</keyword>
</DOC>